26416-23-9

Basic information

• Product Name: 2-(3-fluorophenyl)ethyl 4-methylbenzenesulfonate
• Synonyms: 2-(3-fluorophenyl)ethyl 4-methylbenzenesulfonate
• CAS NO: 26416-23-9
• Molecular Weight: 294.347
• Mol File: 26416-23-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-(3-fluorophenyl)ethyl 4-methylbenzenesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-fluorophenyl)ethyl 4-methylbenzenesulfonate(26416-23-9)
• EPA Substance Registry System: 2-(3-fluorophenyl)ethyl 4-methylbenzenesulfonate(26416-23-9)

Safety Data

• Hazardous Substances Data: 26416-23-9(Hazardous Substances Data)

Upstream product

• 64123-77-9 methyl (3-fluorophenyl)acetate 
• 331-25-9 (3-fluorophenyl)acetic acid 
• 52059-53-7 2-(3-fluorophenyl)ethanol 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 1338349-50-0 N-[2-ethyl-2-(4-fluorophenyl)butyl]-1-[2-(3-fluorophenyl)ethyl]piperidine-4-carboxamide oxalate 
• 467223-91-2 1-fluoro-3-(2-iodoethyl)benzene 
• 1208110-14-8 (2S)-1'-[2-(3-fluorophenyl)ethyl]-6-methoxy-3,4-dihydro-1H-spiro[naphthalene-2,2'-piperidin]-1-one hydrochloride 
• 1208110-12-6 (2S)-1'-[2-(3-fluorophenyl)ethyl]-6-methoxy-3,4-dihydro-1Hspiro[naphthalene-2,2'-piperidin]-1-one 

Relevant articles and documents

Novel pyrrolidine or piperidine derivatives having activity for T-type calcium channel

A pyrrolidine or piperidine compound having activity for T - type calcium channel, wherein the pyrrolidine or piperidine compound of Formula 1 according to the present invention has an excellent antagonistic activity to, T-type calcium channel, and can be used as a preventive or therapeutic agent, for pain diseases, or cancer related to cancer, or cancer such as, epilepsy and,hepatic pain, angina. (by machine translation)

Discovery, synthesis, and structure-activity relations of 3,4-dihydro-1H-spiro(naphthalene-2,2′-piperidin)-1-ones as potassium-competitive acid blockers

With the aim to discover a gastric antisecretory agent more potent than the existing proton pump inhibitors, novel 3,4-dihydro-1H-spiro(naphthalene-2,2′-piperidin)-1-one derivatives, which could occupy two important lipophilic pockets (described as LP-1 and LP-2) of H+,K+-ATPase and can strongly bind to the K+-binding site, were designed based on a docking model. Among the compounds synthesized, compound 4d showed a strong H+,K+-ATPase-inhibitory activity and a high stomach concentration in rats, resulting in potent inhibitory action on histamine-stimulated gastric acid secretion in rats. Furthermore, 4d exerted significant inhibitory action on histamine-stimulated gastric-acid secretion in rats with a rapid onset and moderate duration of action after the administration. These findings may lead to a new insight into the drug design of potassium-competitive acid blockers.